Bluebird Bio | Sustainability Performance
A biotechnology company engaged in the development of gene and cell therapies for severe genetic disorders. It focuses on rare diseases, with therapies that aim to modify or correct the underlying genetic cause.
1992
United States
201 - 500 employees
Biotechnology
$25M - 100M in revenue
Not profitable
Sustainability Ranking & Industry Benchmark
#11384
Overall#2559
in United States#225
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Governance
TargetsESG scores and ExclusionsFinancial Data
Business performanceCapital & innovationAnalyst projections
Market cap
Revenue
R&D intensity
Controversy level
Powered by illuminem
Market cap
Revenue
EBITDA
Operating margin
P/E ratio
Revenue & EBITDA
$83.0MFY2024 revenue
Total Annual
Revenue & EBITDA
($ B)
Annual revenue
EBITDA
3 year change
Margin trends
Margin as % of revenue
Gross margin
Operating margin
Net margin
Powered by illuminem
Free cashflow
Capex
Debt/equity ratio
R&D intensity
113.3%FY2024
R&D as % of revenue
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Return on invested capital
-176.0%FY2026
Return on invested capital (ROIC)
Industry benchmark
Powered by illuminem
Analyst revenue estimates & actuals
Analyst consensus vs actuals
($ B)
Actual revenue
Consensus estimates
Estimate only
0.0
▼ 92.2%
0.0
▼ 30.0%
0.1
▲ 11.7%
0.5
2030Powered by illuminem
Environmental policy coverage
Carbon reduction policy
Not available
Human rights policy
Not available
Recycling policy
Not available
Workplace health & safety policy
Available
0%
Independent Directors
0 out of 5 incl. management
Overall score
40
Environment
37
Social
20
Governance
63
Exclusion screening
Adult content
Not available
Alcoholic
Not available
Animal testing
Available
Firearms
Not available
Tobacco
Not available
Gambling
Not available
Nuclear
Not available
